PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics

PTC Therapeutics, Inc. (PTCT): $42.57

-1.55 (-3.51%)

POWR Rating

Component Grades








Add PTCT to Watchlist
Sign Up

Industry: Biotech




#64 of 381

in industry

PTCT Price/Volume Stats

Current price $42.57 52-week high $59.84
Prev. close $44.12 52-week low $25.01
Day low $42.26 Volume 599,300
Day high $43.92 Avg. volume 819,090
50-day MA $50.99 Dividend yield N/A
200-day MA $46.60 Market Cap 3.16B

PTCT Stock Price Chart Interactive Chart >


  • Momentum is the dimension where PTCT ranks best; there it ranks ahead of 78.35% of US stocks.
  • PTCT's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • PTCT's current lowest rank is in the Stability metric (where it is better than 11.91% of US stocks).

PTCT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PTCT is -1.68 -- better than just 4.7% of US stocks.
  • Of note is the ratio of PTC THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 12.72% of US stocks have a lower such ratio.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -5.52 for PTC THERAPEUTICS INC; that's greater than it is for merely 3.27% of US stocks.
  • Stocks that are quantitatively similar to PTCT, based on their financial statements, market capitalization, and price volatility, are INFI, VERU, CDXS, MRNS, and SAGE.
  • Visit PTCT's SEC page to see the company's official filings. To visit the company's web site, go to

PTCT Valuation Summary

  • In comparison to the median Healthcare stock, PTCT's price/sales ratio is 9.8% higher, now standing at 5.6.
  • PTCT's price/sales ratio has moved down 5.2 over the prior 121 months.

Below are key valuation metrics over time for PTCT.

Stock Date P/S P/B P/E EV/EBIT
PTCT 2023-05-23 5.6 -9.5 -7.6 -9.6
PTCT 2023-05-22 5.7 -9.6 -7.7 -9.7
PTCT 2023-05-19 5.6 -9.5 -7.6 -9.6
PTCT 2023-05-18 5.6 -9.4 -7.5 -9.6
PTCT 2023-05-17 5.6 -9.5 -7.6 -9.6
PTCT 2023-05-16 5.2 -8.8 -7.0 -9.0

PTCT Growth Metrics

    Its 2 year revenue growth rate is now at 77.02%.
  • The 3 year cash and equivalents growth rate now stands at -28.32%.
  • Its 4 year net cashflow from operations growth rate is now at -51.61%.
Over the past 49 months, PTCT's revenue has gone up $440,191,000.

The table below shows PTCT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 696.617 -259.531 -531.393
2022-06-30 618.233 -272.676 -555.702
2022-03-31 569.383 -248.579 -521.985
2021-12-31 538.593 -251.332 -523.901
2021-09-30 492.225 -246.858 -454.99
2021-06-30 471.886 -169.009 -391.058

PTCT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PTCT has a Quality Grade of C, ranking ahead of 45.84% of graded US stocks.
  • PTCT's asset turnover comes in at 0.235 -- ranking 183rd of 682 Pharmaceutical Products stocks.
  • NMTR, ZIOP, and ATXS are the stocks whose asset turnover ratios are most correlated with PTCT.

The table below shows PTCT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.235 0.943 -0.271
2021-06-30 0.221 0.945 -0.205
2021-03-31 0.216 0.944 -0.305
2020-12-31 0.205 0.950 -0.360
2020-09-30 0.210 0.951 -0.473
2020-06-30 0.198 0.949 -0.648

PTCT Price Target

For more insight on analysts targets of PTCT, see our PTCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $61.58 Average Broker Recommendation 1.77 (Moderate Buy)

PTC Therapeutics, Inc. (PTCT) Company Bio

PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.

PTCT Latest News Stream

Event/Time News Detail
Loading, please wait...

PTCT Latest Social Stream

Loading social stream, please wait...

View Full PTCT Social Stream

Latest PTCT News From Around the Web

Below are the latest news stories about PTC THERAPEUTICS INC that investors may wish to consider to help them evaluate PTCT as an investment opportunity.

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:

Yahoo | June 2, 2023

3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs

Small-cap stocks can be risky, and all three of these companies are facing adversity.

Ian Bezek on InvestorPlace | May 31, 2023

PTC Therapeutics, Inc. (NASDAQ:PTCT) Might Not Be As Mispriced As It Looks After Plunging 25%

PTC Therapeutics, Inc. ( NASDAQ:PTCT ) shareholders won't be pleased to see that the share price has had a very rough...

Yahoo | May 31, 2023

Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates

Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both companies.

Yahoo | May 25, 2023

Why Is Apexigen (APGN) Stock Up 31% Today?

Apexigen (APGN) stock is rising higher on Wednesday following news of a $16 million acquisition deal with Pyxis Oncology (PYXS).

William White on InvestorPlace | May 24, 2023

Read More 'PTCT' Stories Here

PTCT Price Returns

1-mo -23.74%
3-mo -11.66%
6-mo 11.21%
1-year 58.02%
3-year -15.67%
5-year 17.01%
YTD 11.53%
2022 -4.17%
2021 -34.74%
2020 27.07%
2019 39.95%
2018 105.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!